Suchergebnisse - (Person:"Xiang, Yi")

PubPharm (12)

1

Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma

enthalten in: Scientific reports | 2021

von Yu, D. | Chen, X. | Li, X. | +8

2

Molecular alterations and clinical relevance in cervical carcinoma and precursors (Review)

enthalten in: Oncology reports | 2020

von Sheng, J. | Xiang, Y. | Shang, L. | +1

3

Decreased let-7b is associated with poor prognosis in glioma

enthalten in: Medicine | 2019

von Zhang, W. | Zhao, W. | Ge, C. | +4

4

Clinicopathological significance of miR-27b targeting Golgi protein 73 in patients with hepatocellular carcinoma

enthalten in: Anti-cancer drugs | 2019

von Liang, H. | Ai-Jun, J. | Ji-Zong, Z. | +4

5

Expressions of Matrix Metalloproteinases-9 and Tissue Inhibitor of Metalloproteinase-1 in Pituitary Adenomas and Their Relationships with Prognosis

enthalten in: Cancer biotherapy & radiopharmaceuticals | 2019

von Guo, H. | Sun, Z. | Wei, J. | +6

6

A secretomic study on human hepatocellular carcinoma multiple drug-resistant cell lines

enthalten in: Oncology reports | 2015

von Xiang, Y. | Liu, Y. | Yang, Y. | +4

7

C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma

enthalten in: International journal of oncology | 2015

von She, S. | Xiang, Y. | Yang, M. | +15

8

Advances in pancreatic cancer research : moving towards early detection

enthalten in: World journal of gastroenterology | 2014

von He, X. | Yuan, Y.

9

Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition

enthalten in: Oncology reports | 2013

von Qian, Y. | Guo, Y. | Wan, H. | +5

10

Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men

enthalten in: Asian Pacific journal of cancer prevention : APJCP | 2012

von Zheng, X. | Zhang, P. | Xie, L. | +3